Free tool
FAERS Monitor: Jadenu
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206910 or its brand name (Jadenu, Deferasirox). Reports on generic versions are filed under their own applications.
Reports
6,732
Serious
4,874
72% of reports
Hospitalization
2,507
Death reported
1,125
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death696
- sickle cell anaemia with crisis563
- diarrhoea478
- off label use419
- nausea335
- haemoglobin decreased312
- pyrexia310
- drug ineffective286
- fatigue272
- vomiting250
- anaemia216
- abdominal pain210
- serum ferritin increased208
- pneumonia196
- product dose omission issue194
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 14 |
| 2009 | 16 |
| 2010 | 31 |
| 2011 | 37 |
| 2012 | 73 |
| 2013 | 44 |
| 2014 | 44 |
| 2015 | 213 |
| 2016 | 518 |
| 2017 | 585 |
| 2018 | 599 |
| 2019 | 658 |
| 2020 | 750 |
| 2021 | 675 |
| 2022 | 757 |
| 2023 | 536 |
| 2024 | 496 |
| 2025 | 368 |
| 2026 | 313 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,427 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| serum ferritin increasedSignal | 208 | 128.2 | 111.8 | 25,104 |
| sickle cell anaemia with crisisSignal | 563 | 115.7 | 106.7 | 61,675 |
| haemoglobin decreasedSignal | 312 | 9.5 | 8.5 | 2,375 |
| anaemiaSignal | 216 | 3.5 | 3.1 | 395 |
| abdominal painSignal | 210 | 2.8 | 2.5 | 248 |
| pyrexiaSignal | 310 | 2.8 | 2.5 | 363 |
| deathSignal | 696 | 2.5 | 2.4 | 666 |
| diarrhoeaSignal | 478 | 2.3 | 2.1 | 367 |
| product dose omission issueSignal | 194 | 2.1 | 1.8 | 106 |
| pneumonia | 196 | 1.9 | 1.6 | 83 |
| vomiting | 250 | 1.7 | 1.5 | 67 |
| off label use | 419 | 1.5 | 1.4 | 71 |
| nausea | 335 | 1.3 | 1.2 | 27 |
| fatigue | 272 | 1.1 | 1.0 | 2 |
| drug ineffective | 286 | 0.7 | 0.6 | 46 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.